The demand for lithium is set to grow 20X by 2040, creating a major opportunity for investors. Elon Musk described it as "like minting money." Enter EnergyX. Their tech can extract 300% more lithium, earning them $100M+ in investments from GM and others.
|
|
Below is an important message from one of our highly valued partners and today's top news. |
|
|
|
The Next Gold Rush? - Ad The demand for lithium is set to grow 20X by 2040, creating a major opportunity for investors. Elon Musk described it as "like minting money." Enter EnergyX. Their tech can extract 300% more lithium, earning them $100M+ in investments from GM and others. More Info ➔ | Disclosure: This is a paid advertisement for EnergyX's Regulation A+ Offering. Please read the offering circular at invest.energyx.com |
|
|
Oil = Monthly Income - Ad Right now, there's an unusual $25 way to collect MONTHLY income from the oil markets. It's not a stock, bond, or anything you've likely heard about... But it's by far my #1 investment opportunity for 2024. Find out more right now |
|
|
Kamala Harris May Seize This Cutting-Edge Tech -- Act Now - Ad A new technology (not AI) is powerful enough to save America $1.7 TRILLION in healthcare costs each year. Trump is rumored to use it personally... And Kamala Harris has threatened to have key patents on it seized. Whoever wins the election - it could cause a massive surge in demand... And send a tiny firm with key patents on this technology soaring. It's currently trading for only $7. But it likely won't stay this cheap for long. Get the ticker here before it soars |
|
|
8 Stocks Wall Street Analysts Love Most - Ad When in doubt over picking which stocks to own it's wise to look at what the experts are saying. Here are the 8 stocks with the highest percentage of buy ratings among analysts on Wall Street today.
|
| | By clicking the link above you will automatically opt-in to receive emails from TechnicalTrading and agree to Privacy Policy |
|
|
|
If You Wait for FDA Approval, It Could Be Too Late ... - Ad Biotech stocks can be incredibly rewarding, but picking the right ones is nearly impossible without a PhD or insider knowledge. The FDA approval process is long and costly, and 9 out of 10 drugs never make it. However, a special FDA signal has led to stock spikes 97% of the time, regardless of approval. More Info ➔ |
|
|
|
Information, charts or examples contained in this email are for illustration and educational purposes only and not for individualized investment management. This message contains commercial elements, such as advertising as well as partner offers for which we may receive affiliate compensation. We only send these offers to those who have opted in to our newsletter. If you wish to no longer receive these offers click on the unsubscribe link at the bottom of this email. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained in this email or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault. 339-20 De Boers Dr., Toronto, ON M3J 0H1, 917.672.7040 © 2024 Musth | MarketHundred | All rights reserved. Unsubscribe |
|
|
|